PIK3CA and Hyperglycemia: All together, we validate that BYL-719 and CNIO-PI3Ki are inhibiting PI3Kɑ in vivo by using a number of on-target readouts (hyperglycemia, increased serum lipids, and reduced serum lactate), whereas these effects are absent upon treatment with GS-9820.